沙利度胺与赛庚啶联合治疗肝细胞癌（HCC）伴肺转移出现意外缓解：两例报告及HCC细胞系初步研究
Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study.
作者信息
Feng Yu-Min, Feng Chin-Wen, Chen Solomon Chih-Cheng, Hsu Cheng-Da
机构信息
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.
出版信息
BMJ Case Rep. 2012 Oct 12;2012:bcr2012007180. doi: 10.1136/bcr-2012-007180.
Abstract
We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine. The use of cyproheptadine in these two cases was originally for skin itching. Follow-up CT images revealed a complete remission of HCC in both of them after treatment for 6 months and 6 weeks, respectively. A following experimental cell line study demonstrated that cyproheptadine effectively reduced the viability of two HCC cell lines.
摘要
我们报告了两例肝细胞癌（HCC）伴肺转移的患者，他们接受了沙利度胺和赛庚啶联合治疗。在这两例患者中，赛庚啶最初用于治疗皮肤瘙痒。随访CT图像显示，分别在治疗6个月和6周后，两例患者的肝癌均完全缓解。随后的实验细胞系研究表明，赛庚啶可有效降低两种肝癌细胞系的活力。
相似文献
1
Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study.沙利度胺与赛庚啶联合治疗肝细胞癌（HCC）伴肺转移出现意外缓解：两例报告及HCC细胞系初步研究
BMJ Case Rep. 2012 Oct 12;2012:bcr2012007180. doi: 10.1136/bcr-2012-007180.
2
Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.赛庚啶是一种抗组胺药，它通过激活P38丝裂原活化蛋白激酶来阻断细胞周期进程，从而抑制肝癌细胞的增殖。
BMC Cancer. 2015 Mar 17;15:134. doi: 10.1186/s12885-015-1137-9.
3
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.赛庚啶显著提高了索拉非尼治疗的晚期肝癌患者的总生存期和无进展生存期。
Jpn J Clin Oncol. 2015 Apr;45(4):336-42. doi: 10.1093/jjco/hyv007. Epub 2015 Feb 2.
4
5
[Complete remission of hepatocellular carcinoma with multiple lung metastases by oral administration of tegafur/uracil].口服替加氟/尿嘧啶实现伴有多发肺转移的肝细胞癌完全缓解
Gan To Kagaku Ryoho. 2013 Aug;40(8):1077-80.
6
A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.表柔比星与沙利度胺治疗不可切除或转移性肝细胞癌的II期研究。
Oncologist. 2005 Jun-Jul;10(6):392-8. doi: 10.1634/theoncologist.10-6-392.
7
8
Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study.沙利度胺治疗转移性肝细胞癌：一项初步研究。
Korean J Intern Med. 2006 Dec;21(4):225-9. doi: 10.3904/kjim.2006.21.4.225.
9
Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin.奥沙利铂治疗后残余肝癌在裸鼠模型中具有增加的转移潜能，而松友饮可减弱其转移潜能。
BMC Cancer. 2010 May 20;10:219. doi: 10.1186/1471-2407-10-219.
10
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.沙利度胺和卡培他滨治疗晚期肝细胞癌患者的疗效。
Am J Clin Oncol. 2012 Jun;35(3):222-7. doi: 10.1097/COC.0b013e31820dbf56.
引用本文的文献
1
Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma.表观遗传调控在尿路上皮癌中引发自然杀伤细胞介导的免疫反应。
Mol Med. 2025 Jun 24;31(1):247. doi: 10.1186/s10020-025-01264-9.
2
Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring.赛庚啶抑制体外和体内肺转移并驱动代谢重编程。
Mol Biol Rep. 2024 Nov 10;51(1):1139. doi: 10.1007/s11033-024-10033-6.
3
Chest wall mass as a sign of ignored hepatocellular carcinoma in an alcoholic cirrhotic patient: a case report.酒精性肝硬化患者中胸壁肿块作为被忽视的肝细胞癌的体征：一例报告
Ann Med Surg (Lond). 2023 Jun 20;85(8):4092-4095. doi: 10.1097/MS9.0000000000001007. eCollection 2023 Aug.
4
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.当前和新型的肝细胞癌药理学治疗方法。
World J Gastroenterol. 2023 May 7;29(17):2571-2599. doi: 10.3748/wjg.v29.i17.2571.
5
Association of Antihistamine Use with Increased Risk of Esophageal Squamous Cell Carcinoma: A Nationwide, Long-Term Follow-Up Study Using Propensity Score Matching.抗组胺药使用与食管鳞状细胞癌风险增加的关联：一项基于倾向评分匹配的全国性长期随访研究
Biomedicines. 2023 Feb 16;11(2):578. doi: 10.3390/biomedicines11020578.
6
H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection.H1 抗组胺药可降低乙型肝炎病毒、丙型肝炎病毒或乙型肝炎病毒-丙型肝炎病毒双重感染患者发生肝细胞癌的风险。
J Clin Oncol. 2022 Apr 10;40(11):1206-1219. doi: 10.1200/JCO.21.01802. Epub 2022 Jan 19.
7
Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report.赛庚啶单药治疗肝细胞癌骨转移的疗效：一例报告
Front Oncol. 2021 Oct 20;11:620212. doi: 10.3389/fonc.2021.620212. eCollection 2021.
8
OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.OPALS：使用五种重新定位药物的奥希替尼辅助治疗肺腺癌或胶质母细胞瘤的新方法。
Cells. 2021 May 10;10(5):1148. doi: 10.3390/cells10051148.
9
Analysis of the effects of cyproheptadine on bladder cancer through big data.通过大数据分析赛庚啶对膀胱癌的影响。
Am J Cancer Res. 2020 Jul 1;10(7):2114-2119. eCollection 2020.
10
The Antihistamine Deptropine Induces Hepatoma Cell Death through Blocking Autophagosome-Lysosome Fusion.抗组胺药去托品通过阻断自噬体-溶酶体融合诱导肝癌细胞死亡。
Cancers (Basel). 2020 Jun 18;12(6):1610. doi: 10.3390/cancers12061610.
本文引用的文献
1
Loratadine dysregulates cell cycle progression and enhances the effect of radiation in human tumor cell lines.氯雷他定扰乱细胞周期进程，并增强辐射对人肿瘤细胞系的作用。
Radiat Oncol. 2010 Feb 3;5:8. doi: 10.1186/1748-717X-5-8.
2
Serotonin promotes tumor growth in human hepatocellular cancer.血清素促进人肝癌肿瘤生长。
Hepatology. 2010 Apr;51(4):1244-54. doi: 10.1002/hep.23441.
3
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.抗组胺药赛庚啶通过作为组蛋白去乙酰化酶抑制剂的作用，与硼替佐米协同增强套细胞淋巴瘤的抗肿瘤活性。
Br J Haematol. 2009 Sep;146(6):656-9. doi: 10.1111/j.1365-2141.2009.07797.x. Epub 2009 Jul 8.
4
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
5
Cyproheptadine displays preclinical activity in myeloma and leukemia.赛庚啶在骨髓瘤和白血病中显示出临床前活性。
Blood. 2008 Aug 1;112(3):760-9. doi: 10.1182/blood-2008-02-142687. Epub 2008 May 23.
6
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.低剂量沙利度胺作为晚期肝细胞癌患者一线全身治疗的疗效和耐受性
Oncology. 2007;72 Suppl 1:67-71. doi: 10.1159/000111709. Epub 2007 Dec 13.
7
Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest.选择性环氧化酶-2抑制剂NS-398通过细胞周期阻滞抑制人肝癌细胞系中的细胞增殖。
World J Gastroenterol. 2007 Feb 28;13(8):1175-81. doi: 10.3748/wjg.v13.i8.1175.
8
Management of hepatocellular carcinoma.肝细胞癌的管理
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
9
Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience.高发病率国家肝细胞癌死亡率上升的原因：台湾地区的经验
J Gastroenterol Hepatol. 2005 Apr;20(4):521-6. doi: 10.1111/j.1440-1746.2005.03602.x.
10
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate.沙利度胺诱导的抗血管生成作用是由神经酰胺通过消耗血管内皮生长因子（VEGF）受体介导的，并且被1-磷酸鞘氨醇拮抗。
Blood. 2005 Jul 1;106(1):125-34. doi: 10.1182/blood-2004-09-3679. Epub 2005 Mar 1.
Zotero 插件